Literature DB >> 35441353

Adjuvant therapy in early-stage cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis.

Natalia R Gómez-Hidalgo1, Úrsula Acosta2, Tomás Gómez Rodríguez3, Soraya Mico4, Ramona Verges4, Vicente Bebia Conesa2, Melissa Bradbury2, Santiago Pérez-Hoyos5, Asunción Pérez-Benavente2, Antonio Gil-Moreno2,6.   

Abstract

OBJECTIVE: There is a gap in knowledge regarding the ideal management of patients with early-stage cervical cancer and intermediate-risk features. Here, we present a meta-analysis of the published literature on oncological outcomes in these patients and determine trends in postoperative management.
METHODS: MEDLINE and PubMed were used for literature searches. The inclusion criteria were: English language articles including ≥ 10 patients, patients who underwent radical hysterectomy, nodes negative, studies reporting oncological outcomes and complications treatment-related and compare a surgery-only cohort with a radiotherapy cohort. The PRISMA guidelines were followed. Combined relative risk was calculated using DerSimonian-Laird random-effects model and a forest plot was drawn.
RESULTS: We collected 183 manuscripts on early-stage cervical cancer treated with radical hysterectomy alone or with adjuvant radiotherapy after surgery. A total of eight studies met the inclusion criteria. Regarding oncological outcomes, survival was reported in five studies. The relative risk of recurrence and the relative risk of mortality was similar in both groups independently whether receive or not adjuvant therapy. Most of the studies did not report significant differences regarding morbidity treatment related between the groups, except for a higher rate of lymphedema after radiotherapy.
CONCLUSION: We found that the relative risk of recurrence and mortality was similar in both groups not depending on adjuvant therapy. Therefore, whether radiotherapy adjuvant treatment is indicated remains a topic of debate.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Adjuvant radiotherapy; Cervical cancer surgery; Early-stage cervical cancer; Intermediate-risk factors

Mesh:

Year:  2022        PMID: 35441353     DOI: 10.1007/s12094-022-02808-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  12 in total

Review 1.  Radiotherapy and chemoradiation after surgery for early cervical cancer.

Authors:  Linda Rogers; Shing Shun N Siu; David Luesley; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy.

Authors:  Denis Querleu; David Cibula; Nadeem R Abu-Rustum
Journal:  Ann Surg Oncol       Date:  2017-08-07       Impact factor: 5.344

3.  Radical pelvic surgery versus radical surgery plus radiotherapy for stage Ib carcinoma of the cervix uteri. Preliminary results of a prospective randomized clinical study.

Authors:  K Bilek; K Ebeling; H Leitsmann; G Seidel
Journal:  Arch Geschwulstforsch       Date:  1982-05

4.  The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer.

Authors:  David Cibula; Richard Pötter; François Planchamp; Elisabeth Avall-Lundqvist; Daniela Fischerova; Christine Haie Meder; Christhardt Köhler; Fabio Landoni; Sigurd Lax; Jacob Christian Lindegaard; Umesh Mahantshetty; Patrice Mathevet; W Glenn McCluggage; Mary McCormack; Raj Naik; Remi Nout; Sandro Pignata; Jordi Ponce; Denis Querleu; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Pauline Wimberger; Maria Rosaria Raspollini
Journal:  Int J Gynecol Cancer       Date:  2018-05       Impact factor: 3.437

5.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.

Authors:  P W Grigsby; B A Siegel; F Dehdashti
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

6.  Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

Review 7.  Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.

Authors:  David Cibula; Nadeem R Abu-Rustum; Daniela Fischerova; Selvan Pather; Katie Lavigne; Jiri Slama; Kaled Alektiar; Lin Ming-Yin; Roman Kocian; Anna Germanova; Filip Frühauf; Lukas Dostalek; Ladislav Dusek; Kailash Narayan
Journal:  Gynecol Oncol       Date:  2018-10-20       Impact factor: 5.482

8.  European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer.

Authors:  David Cibula; François Planchamp; Daniela Fischerova; Christina Fotopoulou; Christhardt Kohler; Fabio Landoni; Patrice Mathevet; Raj Naik; Jordi Ponce; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Cagatay Taskiran; Ignace Vergote; Pauline Wimberger; Ane Gerda Zahl Eriksson; Denis Querleu
Journal:  Int J Gynecol Cancer       Date:  2020-01       Impact factor: 3.437

9.  A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.

Authors:  Chien-Sheng Tsai; Chyong-Huey Lai; Ting-Chang Chang; Tzu-Chen Yen; Koon-Kwan Ng; Swei Hsueh; Steve P Lee; Ji-Hong Hong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

10.  Minimally invasive surgery using intraoperative electron-beam radiotherapy for the treatment of soft tissue sarcoma of the extremities with tendon involvement.

Authors:  Akihiko Matsumine; Masaya Tsujii; Tomoki Nakamura; Kunihiro Asanuma; Takao Matsubara; Takuya Kakimoto; Yuki Yada; Akinori Takada; Noriko Ii; Yoshihito Nomoto; Akihiro Sudo
Journal:  World J Surg Oncol       Date:  2016-08-12       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.